share_log

Roth MKM Initiates Coverage On Immix Biopharma With Buy Rating, Announces Price Target of $14

Roth MKM Initiates Coverage On Immix Biopharma With Buy Rating, Announces Price Target of $14

Roth MKM 开始对Immix Biopharma进行报道,评级为买入,宣布目标价为14美元
Benzinga Real-time News ·  2023/02/22 08:21

Roth MKM analyst Jonathan Aschoff initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $14.

Roth MKM分析师Jonathan Aschoff在ImMix Biophma(纳斯达克:IMMX)上以买入评级启动报道,并宣布目标价为14美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发